Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.39 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.39 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.36 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL181010 | 0.83 | ABL1 (0.46) | ABL1BCREPHX2TRPV4CYP2C9 | |
| SCHEMBL180474 | 0.81 | ABL1 (0.48) | ABL1BCREPHX2TRPV4CYP2C9 | |
| SCHEMBL181112 | 0.78 | ABL1 (0.57) | ABL1BCREPHX2TRPV4CYP2C9 | |
| SCHEMBL17195464 | 0.76 | GRM5 (0.43) | SLC22A12BACE2 | |
| SCHEMBL26107386 | 0.75 | ABL1 (0.48) | ABL1BCREPHX2TRPV4TRPV1 | |
| SCHEMBL2484911 | 0.74 | TAS2R14 (0.45) | — | |
| SCHEMBL17396429 | 0.71 | ABL1 (0.50) | ABL1BCREPHX2TRPV4CYP2C9 | |
| SCHEMBL22212784 | 0.71 | CYP2C9 (0.50) | ABL1BCREPHX2TRPV4CYP2C9 | |
| SCHEMBL262560 | 0.71 | TRPV4 (0.43) | TRPV4 | |
| SCHEMBL29686705 | 0.70 | NNMT (0.50) | ABL1BCRCDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2916839-B1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-10-11 | — | — | EP | disclosed |
| EP-2916839-B1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2017-10-11 | — | — | EP | disclosed |
| US-9624174-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624174-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2017-04-18 | — | — | US | disclosed |
| US-20160068487-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC | 2016-03-10 | — | — | US | disclosed |
| US-20160068487-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC | 2016-03-10 | — | — | US | disclosed |
| US-9221766-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221766-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150299138-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE LLC | 2015-10-22 | — | — | US | disclosed |
| EP-2916839-A2 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | Glaxosmithkline LLC (US) | 2015-09-16 | — | — | EP | disclosed |
| EP-2404905-A1 | New compounds | Novartis AG (CH) | 2012-01-11 | — | — | EP | disclosed |
| EP-2402319-A1 | DGAT Inhibitors | Novartis AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402320-A1 | Anorectic agents | Novartis AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402318-A1 | DGAT inhibitors | Novartis AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2402317-A1 | DGAT inhibitor | Novartis AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| EP-2301923-A1 | New compounds | Novartis AG (CH) | 2011-03-30 | — | — | EP | disclosed |
| US-20090247534-A1 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2009-10-01 | — | — | US | disclosed |
| CN-101415683-A | Novel compounds | NOVARTIS AG (CH) | 2009-04-22 | — | — | CN | disclosed |
| EP-2004607-A2 | NEW COMPOUNDS | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007126957-A2 | NEW COMPOUNDS | NOVARTIS AG (CH) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247534-A1 | NEW COMPOUNDS | DGAT1, DGAT2, GBA1 | ABL1 3908/4885BCR 2341/4885EPHX2 1740/4885 |
| US-20150299138-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | ABL1 2193/4885BCR 1254/4885EPHX2 1177/4885 |
| US-20160068487-A1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | DGAT1, DGAT2, LCAT | ABL1 2193/4885BCR 1254/4885EPHX2 1177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.